International Journal of Environmental and Biological Sciences Articles Publishing terms and rules Vol. 1 No. 4 (2026): Fourth Issue - October 2026 2026-10-31

Serum Interleukin-33 Levels and Their Association with Insulin Resistance and Hormonal Alterations in Women with Polycystic Ovary Syndrome: A Case–Control Study Polycystic Ovary Syndrome

01Abstract

Background: Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder associated with metabolic imbalances and chronic inflammation. Interleukin-33 (IL-33) has been suggested as a biomarker for inflammation in a number of diseases. Aim of this study: To assess serum IL-33 levels in women with PCOS compared to healthy controls and to analyze its predictive capabilities as diagnostic marker for PCOS. Materials and Methods: A total of 180 women participated aged (18-40) years in the study included   90 newly diagnosed with PCOS and 90 healthy control groups in a case-control study. Serum IL-33 level was measured using an enzyme-linked immunosorbent assay. Clinical parameters such as BMI, fasting insulin (FIN) and homeostasis model assessment of insulin resistance (HOMA-IR) were measured. Besides IL-33 levels, clinical parameters such as LH, FSH, total testosterone and estradiol were also measured, and significant differences and correlations were obtained, which were all suggestive of metabolic and reproductive dysfunction associated with PCOS. The Receiver Operating Characteristic (ROC) curve analysis was used to determine the diagnostic value of IL-33 levels, and Random Forest and Support Vector Machine (SVM) classifiers were used to see how well the levels of IL-33 could predict the disease. Results: The level of serum IL-33 was found to be significantly elevated in women with PCOS (75.4 ± 12.8 pg/mL) when compared with healthy controls (34.6 ± 8.5 pg/mL, p < 0.001).  Positive correlations were observed between IL-33 level and BMI (r = 0.681,p<0.001 ), fasting insulin (r = 0.575, p<0.001), HOMA-IR (r = 0.752, p<0.001), LH (r = 0.493,p<0.001), FSH (r = 0.431,p = 0.005), LH/FSH Ratio (r = 0.484,p<0.001), Total Testosterone (r = 0.309,p<0.001), Free Testosterone (r = 0.526, p<0.001), Prolactin (r = 0.250,p = 0.062), Progesterone (r = 0.423,p = 0.007), Estradiol (E2) (r = 0.397,p<0.001) and Sex hormone binding globulin (SHBG) (r =-0.506,p<0.001) in women with PCOS group. ROC analysis was performed and resulted in an outstanding AUC value of 0.962 (95% CI: 0.934–0.990), which demonstrates excellent discrimination between PCOS and healthy subjects, with an optimal cut-off value of > 50.91 pg/mL, a sensitivity of 91.1% and a specificity of 90.0%. Conclusions: Overall, this study indicates a significant association between increased serum IL-33 levels and the inflammatory and metabolic changes seen in women with PCOS. Overall, these results highlight the promising potential of IL-33 as a valuable biomarker in the context of metainflammation in PCOS, given the high AUC values and the effectiveness of the machine learning models. These findings may have important implications for improving the diagnosis and management of PCOS and its associated complications.

Keywords Interleukin -33 Insulin Resistance Metainflammation Polycystic Ovary Syndrome

02Authors

Israa Jafar kadhem
University of Kufa, College of Dentistry, Department of Basic Sciences
Maysam Ali Hadi Eidans
Noor Hassan Abdulrudha

03Article Details

Section
Articles Publishing terms and rules
Pages
30-45
Published
2026-10-31

How to Cite

Serum Interleukin-33 Levels and Their Association with Insulin Resistance and Hormonal Alterations in Women with Polycystic Ovary Syndrome: A Case–Control Study: Polycystic Ovary Syndrome. (2026). International Journal of Environmental and Biological Sciences, 1(4), 30-45. https://doi.org/10.63939/sbe1vy96

04References

  1. 1. Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37(5):467–520.
  2. 2. Palomba S, Santagni S, Falbo A, La Sala GB. Complications and challenges associated with polycystic ovary syndrome: current perspectives. Int J Womens Health. 2015;745–63.
  3. 3. Rani S, Chandna P. Multiomics analysis–based biomarkers in diagnosis of polycystic ovary syndrome. Reprod Sci. 2023;30(1):1–27.
  4. 4. Dey R, Bhattacharya K, Basak AK, Paul N, Bandyopadhyay R, Chaudhuri GR, et al. Inflammatory perspectives of polycystic ovary syndrome: role of specific mediators and markers. Middle East Fertil Soc J. 2023;28(1):33.
  5. 5. Niinuma SA, Lubbad L, Lubbad W, Moin ASM, Butler AE. The role of heat shock proteins in the pathogenesis of polycystic ovarian syndrome: a review of the literature. Int J Mol Sci. 2023;24(3):1838.
  6. 6. Szukiewicz D. Molecular mechanisms for the vicious cycle between insulin resistance and the inflammatory response in obesity. Int J Mol Sci. 2023;24(12):9818.
  7. 7. Singh S, Pal N, Shubham S, Sarma DK, Verma V, Marotta F, et al. Polycystic ovary syndrome: etiology, current management, and future therapeutics. J Clin Med. 2023;12(4):1454.
  8. 8. Cayrol C, Girard JP. Interleukin-33 (IL-33): A critical review of its biology and the mechanisms involved in its release as a potent extracellular cytokine. Cytokine. 2022;156:155891.
  9. 9. Murdaca G, Greco M, Tonacci A, Negrini S, Borro M, Puppo F, et al. IL-33/IL-31 axis in immune-mediated and allergic diseases. Int J Mol Sci. 2019;20(23):5856.
  10. 10. Ciraci E, Elgun T, Yurttas AG, Kuzey HC, Merdan YE, Toprak MS, et al. Evaluation of serum placenta-specific gene 8 protein, total antioxidant capacity, interleukin-10, interleukin-17A, interleukin-21 and interleukin-33 levels in Turkish women with gestational diabetes mellitus. Endocrinol Diabetes y Nutr (English ed). 2024;71(1):12–8.
  11. 11. Sitzia C, Vianello E, Dozio E, Kalousová M, Zima T, Brizzola S, et al. Unveiling IL-33/ST2 Pathway Unbalance in Cardiac Remodeling Due to Obesity in Zucker Fatty Rats. Int J Mol Sci. 2023;24(3):1991.
  12. 12. Liu L, Liu S, Bai F, Deng Y, Zhang X, Wang L. Investigating the role of inflammatory response in polycystic ovary syndrome using integrated RNA-Seq analysis. J Inflamm Res. 2024;4701–19.
  13. 13. Jasim RA, Umran MA, Humadi EH. Correlation Between Serum Interleukinslevels with Anthropometric Data and Lipid Profiles in Obese Iraqi Women With Polycystic Ovary Syndrome. Iraqi J Sci. 2020;68–76.
  14. 14. Zhang Z, Huang L, Brayboy L. Macrophages: an indispensable piece of ovarian health. Biol Reprod. 2021;104(3):527–38.
  15. 15. Varghese M, Song J, Singer K. Age and sex: impact on adipose tissue metabolism and inflammation. Mech Ageing Dev. 2021;199:111563.
  16. 16. Blight LF, Judd SJ, White GH. Relative diagnostic value of serum non-SHBG-bound testosterone, free androgen index and free testosterone in the assessment of mild to moderate hirsutism. Ann Clin Biochem. 1989;26(4):311–6.
  17. 17. Gurrici S, Hartriyanti Y, Hautvast J, Deurenberg P. Relationship between body fat and body mass index: differences between Indonesians and Dutch Caucasians. Eur J Clin Nutr. 1998;52(11):779–83.
  18. 18. Desai D. Assessment of HOMA–IR in healthy subjects. J Adv Med Dent Sci Res. 2015;3(3).
  19. 19. Tang M, Sun X, Li P, Deng W, Zhan X, Sun P, et al. IL-33 and soluble ST2 in follicular fluid are associated with premature ovarian insufficiency. Front Endocrinol (Lausanne). 2024;15:1463371.
  20. 20. Gabryelska A, Kuna P, Antczak A, Białasiewicz P, Panek M. IL-33 mediated inflammation in chronic respiratory diseases—understanding the role of the member of IL-1 superfamily. Front Immunol. 2019;10:692.
  21. 21. Zhang Q, Yang Z, Ou X, Zhang M, Qin X, Wu G. The role of immunity in insulin resistance in patients with polycystic ovary syndrome. Front Endocrinol (Lausanne). 2025;15:1464561.
  22. 22. Kakoly NS, Moran LJ, Teede HJ, Joham AE. Cardiometabolic risks in PCOS: a review of the current state of knowledge. Expert Rev Endocrinol Metab. 2019;14(1):23–33.
  23. 23. Oršolić N, Jazvinšćak Jembrek M. Royal jelly: biological action and health benefits. Int J Mol Sci. 2024;25(11):6023.
  24. 24. Dubey P, Reddy S, Sharma K, Johnson S, Hardy G, Dwivedi AK. Polycystic ovary syndrome, insulin resistance, and cardiovascular disease. Curr Cardiol Rep. 2024;26(6):483–95.
  25. 25. Aboeldalyl S, James C, Seyam E, Ibrahim EM, Shawki HED, Amer S. The role of chronic inflammation in polycystic ovarian syndrome—a systematic review and meta-analysis. Int J Mol Sci. 2021;22(5):2734.

Similar Articles

You may also start an advanced similarity search for this article.